These studies suggest that cell-permeable iron, which is clinically used to reduce phosphate levels in dialysis patients, can be repurposed to inhibit VEGFR-2-mediated signaling in endothelial cells and inhibit tumor angiogenesis in vivo. Here, KDR is linked to neoplasm.